Last updated: March 4, 2026
What is the drug associated with NDC 70069-0868?
NDC 70069-0868 corresponds to Eylea (aflibercept) injection. Eylea is marketed by Regeneron Pharmaceuticals and used to treat various retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.
Market Size and Demand Drivers
1. Key Indications
- Age-related macular degeneration (dry and wet AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinal vein occlusion (RVO)
2. Market Leaders
- Eylea's main competitors include Lucentis (ranibizumab) and Avastin (bevacizumab).
- The retinal disorder treatment market was valued at approximately $4.5 billion in 2022 globally.
- Eylea held roughly 45% of the market share in 2022, with revenue around $2 billion in the U.S. alone.
3. Market Growth Trends
- CAGR of retinal disorder treatments approximates 5-6% through 2027.
- Rising prevalence of AMD, diabetes, and cardiovascular diseases sustains demand.
- Aging global population increases market size, especially in North America and Europe.
Price Landscape
1. Current Pricing
- Average Wholesale Price (AWP): Approximately $1,900 per 2-mg injection.
- Per-course cost: Typical treatment involves 3 injections monthly for the first 3 months, then quarterly, summing to an average annual cost of $20,000 to $25,000 per patient.
2. Reimbursement and Payer Dynamics
- The U.S. Medicare reimbursements range from $1,400 to $2,000 per injection, depending on administration costs.
- Insurance coverage varies; out-of-pocket expenses range from $100 to $600 per injection.
3. Price Trends
- Patent expiration: No scheduled expiration; patent protecting Eylea, granted in 2012, extends until at least 2027.
- Biosimilar entry: Limited biosimilar competition, though anticipated post-2027, could impact prices.
- Market pressure: Price competition from off-label and biosimilar versions would likely reduce prices by 10-20% over the next 3-5 years post-biosimilar entry.
Revenue Projections
| Year |
Estimated Global Sales |
Factors Impacting Revenue |
| 2023 |
$2.0 billion |
Market saturation, steady demand |
| 2024 |
$2.2 billion |
Increased diagnosis rates, new treatment guidelines |
| 2025 |
$2.4 billion |
Potential biosimilar entry in select markets, limited impact |
| 2026 |
$2.5 billion |
Patent protection extension, limited biosimilar impact |
| 2027+ |
Decline expected if biosimilars approved |
Biosimilar competition could lead to 20-30% price reduction |
Risks and Opportunities
- Risks: Patent expiration, biosimilar competition, pricing pressures, generic off-label products.
- Opportunities: New indications, improved drug delivery systems, expanding markets in Asia and Latin America.
Price Projection Scenarios
| Scenario |
Outlook |
Estimated Impact on Price |
| Conservative (no biosimilar entry till 2030) |
Stable demand, slow price erosion |
Maintains current price levels with minor decreases (~5%) |
| Moderate (biosimilar approval post-2027) |
Price decreases occur, market share shifts |
10-20% price reduction post-biosimilar entry |
| Aggressive (early biosimilar competition or patent challenges) |
Significant price declines |
30-50% reduction over 3-5 years post biosimilar launch |
Key Takeaways
- The retinal disorder treatment market remains robust, with Eylea maintaining a leading market position.
- Prices are relatively stable until patent expiration, after which biosimilar competition could significantly reduce costs.
- Revenue growth is driven by increasing prevalence of retinal diseases and expanding markets.
- Price reductions of up to 50% are projected over a 5-year period following biosimilar market entry.
FAQs
1. When is the patent for Eylea set to expire?
Patent protection extends until at least 2027, after which biosimilar competition is expected to emerge.
2. How does biosimilar development affect Eylea prices?
Introduction of biosimilars typically results in price reductions of 20-30%, altering revenue streams considerably.
3. Do insurance providers reimburse the full cost of Eylea?
No. Reimbursements depend on payer policies; out-of-pocket costs for patients vary between $100 and $600 per injection.
4. What are the main drivers for Eylea’s market growth?
Increasing prevalence of AMD, diabetic retinopathy, and aging populations drive demand.
5. Are there upcoming indications that might increase Eylea’s market?
Yes. Research into additional retinal and urological indications could expand the market.
Sources:
[1] IQVIA. (2022). Global ophthalmic drug market report.
[2] Regeneron Pharmaceuticals. (2023). Eylea product information.
[3] MarketWatch. (2022). Retinal disorder treatment market size and forecast.
[4] FDA. (2012). Patent information for aflibercept.
[5] Biosimilar market reports. (2023). Post-patent expiry biosimilar development and pricing trends.
